Aethlon Medical, Inc. (AEMD) Earnings Call Transcripts

Aethlon Medical, Inc.'s Latest Earnings Call - June 10, 2026

In the fiscal year ending March 31, 2026, Aethlon Medical reported a net loss of $7.2 million, a significant reduction from the $13.4 million loss in the prior year, reflecting improved operational efficiency. The company achieved a 21.9% decrease in operating expenses to approximately $7.3 million, primarily due to reduced payroll and administrative costs. Management highlighted ongoing advancements in their Hemopurifier platform and the completion of enrollment in the second cohort of their Australian oncology trial, with plans to progress to the final cohort, which could enhance investor sentiment moving forward.

Reported metrics

Guidance from management

Management did not provide specific numerical guidance for the upcoming quarters but emphasized ongoing clinical development and operational efficiency as key priorities.

What management said

Yes. No, we've seen good engagement and commitment from our 3 sites in terms of screening activity. So that remains a positive, bodes well. We did have a few patients that became screen failures for not meeting an inclusion or exclusion criteria. That happens in every study, unavoidable. So -- but the most important thing for me is that the engagement is there and the activity is there.

Yes. I would just call your attention to that prior press release that shows that the EVs, including tumor-derived EVs went down in the first cohort and that there were improvements in T cells and antitumor T cells in the first cohort.

What analysts pressed on

Analysts expressed concerns regarding the timeline and efficacy of ongoing trials, particularly the secondary endpoints related to the Hemopurifier's performance. There were questions about the potential impact of patient screening failures on trial progress and overall study outcomes.

Main topics on the call

• Operational Efficiency — Aethlon Medical achieved a 21.9% reduction in operating expenses year-over-year, totaling approximately $7.3 million. CEO Jim Frakes stated, "the decrease was primarily due to a $1.1 million reduction in payroll and rela...
• Oncology Trial Progress — The company completed enrollment in cohort 2 of its Australian oncology trial and is preparing to advance to cohort 3. Dr. LaRosa noted that the independent data safety monitoring board found "no safety concerns" and rec...
• Hemopurifier Platform Expansion — Aethlon is expanding the Hemopurifier's applications into additional disease areas, including rheumatoid arthritis and chronic kidney disease. The management emphasized the potential of the Hemopurifier as a platform tec...
• Cash Position and Financial Health — As of March 31, 2026, Aethlon reported approximately $5 million in cash and cash equivalents, which supports ongoing clinical activities. Following the fiscal year-end, the company raised approximately $1.85 million thro...

Read the full Aethlon Medical, Inc. transcript (June 10, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 30 Aethlon Medical, Inc. earnings call transcripts on record, spanning February 10, 2020 to June 10, 2026. Based on this history, Aethlon Medical, Inc. reports quarterly. The most recent call on file is dated June 10, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

AEMD

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

30

First call

February 10, 2020

Most recent

June 10, 2026

Reporting cadence

quarterly